CORT Q2 2024 Earnings — Corcept Therapeutics Incorporated Revenue & Financial Results | Market Cap Arena

CORTCorcept Therapeutics Incorporated

$4B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$164M+39.1% YoY

Gross Profit

$161M98.5% margin

Operating Income

$36M21.7% margin

Net Income

$35M21.7% margin

EPS (Diluted)

$0.32

QoQ Revenue Growth

+11.6%

Cash Flow

Operating Cash Flow

$41M

Free Cash Flow

$41M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$715M

Total Liabilities

$118M

Stockholders' Equity

$596M

Cash & Equivalents

$129M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$164M	$118M	+39.1%
Gross Profit	$161M	$116M	+38.9%
Operating Income	$36M	$30M	+20.3%
Net Income	$35M	$28M	+28.9%